Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Director departure
Quarterly results
Appointed director
CC transcript
|
|
ALLOS THERAPEUTICS INC (ALTH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/21/2011 |
BW
| The Law Firm of Weiss & Lurie Announces Investigation of Allos Therapeutics, Inc. |
| 07/20/2011 |
BW
| MURRAY FRANK LLP Investigates Allos Therapeutics, Inc. |
| 07/20/2011 |
BW
| The Briscoe Law Firm and Powers Taylor, LLP Announce Investigation of Allos Therapeutics, Inc. |
| 07/20/2011 |
BW
| Robbins Umeda LLP Announces an Investigation of Allos Therapeutics, Inc. |
| 07/20/2011 |
BW
| Law Office of Brodsky & Smith, LLC Announces Investigation of Allos Therapeutics, Inc. |
| 07/20/2011 |
BW
| The Law Firm of Levi & Korsinsky, LLP Announces Investigation of Allos Therapeutics, Inc. |
| 07/20/2011 |
BW
| Kendall Law Group Investigates Allos Therapeutics, Inc. |
| 06/08/2011 |
BW
| FOLOTYN® Data to be Presented at the Congress of the European Hematology Association and the International Conference on Malignant Lymphoma |
| 05/10/2011 |
BW
| Allos Therapeutics and Mundipharma Announce Strategic Collaboration for FOLOTYN |
| 05/10/2011 |
BW
| Allos Therapeutics Reports First Quarter 2011 Financial Results |
| 03/30/2011 |
BW
| Allos Therapeutics to Present at Upcoming Investor Conferences |
| 03/03/2011 |
BW
| Allos Therapeutics Reports Fourth Quarter and Full Year 2010 Financial Results |
| 03/03/2011 |
BW
| Allos Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of FOLOTYN in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma |
| 02/17/2011 |
BW
| Allos Therapeutics to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011 |
| 12/10/2010 |
BW
| New Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN® Relative to Erlotinib in Advanced Non-Small Cell Lung Cancer |
| 12/05/2010 |
BW
| Updated Results from FOLOTYN® Phase 1 Dose Finding Study Demonstrates Activity in Relapsed or Refractory Cutaneous T-Cell Lymphoma |
| 12/04/2010 |
BW
| Allos Therapeutics Reports New Analyses of FOLOTYN® Data from PROPEL trial in Relapsed or Refractory Peripheral T-Cell Lymphoma |
| 12/04/2010 |
BW
| New Analysis from FOLOTYN® PROPEL Trial Demonstrates Activity in Relapsed or Refractory Transformed Mycosis Fungoides |
| 11/19/2010 |
BW
| New FOLOTYN® Data to Be Presented at the 2010 American Society of Hematology Annual Meeting |
| 11/04/2010 |
BW
| Allos Therapeutics Reports Third Quarter 2010 Financial Results |
| 10/26/2010 |
BW
| Allos Therapeutics to Report Third Quarter 2010 Financial Results on November 4, 2010 |
| 10/11/2010 |
BW
| Allos Therapeutics Announces Presentation of Favorable Survival Data from Randomized Phase 2b Study of FOLOTYN® in Patients with Advanced Non-Small Cell Lung Cancer |
| 09/13/2010 |
BW
| Allos Therapeutics to Present at Upcoming Investor Conferences |
| 07/28/2010 |
BW
| Allos Therapeutics Reports Second Quarter 2010 Financial Results |
| 07/12/2010 |
BW
| Allos Therapeutics to Report Second Quarter 2010 Financial Results on July 28, 2010 |
| 06/11/2010 |
BW
| Allos Therapeutics' FOLOTYN Shows Activity and Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refractory CTCL |
| 05/05/2010 |
BW
| Allos Therapeutics Reports First Quarter 2010 Financial Results |
| 04/27/2010 |
BW
| Allos Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer |
| 04/21/2010 |
BW
| Allos Therapeutics to Report First Quarter 2010 Financial Results on May 5, 2010 |
| 02/24/2010 |
BW
| Allos Therapeutics to Participate in RBC Capital Markets Health Care Conference |
| 02/17/2010 |
BW
| Allos Therapeutics to Report Fourth Quarter and Full Year 2009 Results on March 1, 2010 |
|
|